Drug guidance
Carbonic anhydrase inhibitor eye drops for treating open-angle glaucoma or ocular hypertension
Condition
Eye
1 April 2022
Published on 01 Apr 2022
Last Updated on 01 Apr 2022
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Brinzolamide 1% eye drops; and
Brinzolamide/timolol 1%/0.5% eye drops
in line with their registered indications for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension, in view of acceptable price proposals from the manufacturer.
Subsidy status
Brinzolamide 1% and brinzolamide/timolol 1%/0.5% eye drops are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.
SDL subsidy does not apply to brinzolamide/brimonidine 1%/0/0.2% eye drops in view of unacceptable price proposal from the manufacturer.